Clinical trial
A Single-arm, Open-label, Multicenter Phase II Study of Cadonilimab Combined With Nab -Paclitaxel in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Previously Treated With Immune Checkpoint Inhibitors
NCT05824494 is registered in ClinicalTrials.gov with Women's Hospital School Of Medicine Zhejiang University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm, Open-label, Multicenter Phase II Study of Cadonilimab Combined With Nab -Paclitaxel in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Previously Treated With Immune Checkpoint Inhibitors
- Lead sponsor
- Women's Hospital School Of Medicine Zhejiang University
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- June 30, 2023
- Completion date
- June 30, 2026
- Enrollment
- 58 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
cancer of cervix, cancer of the uterine cervix, cervical cancer, cervical neoplasms, uterine cervical cancer, uterine cervical neoplasms